Ambrilia: Second Quarter 2008 Results Conference Call and Webcast
* Reuters is not responsible for the content in this press release.
MONTREAL, QUEBEC, Jul 31 (MARKET WIRE) --
Ambrilia Biopharma Inc. (TSX: AMB) today announced that it will be
hosting a conference call and webcast on Monday, August 11, 2008, at 9:00
am ET, to discuss the financial results for its second quarter ended June
30, 2008, and the recent developments. Prior to the conference call, a
press release will be issued on Friday, August 8, after market close. The
call will be hosted by Dr. Philippe Calais, President and Chief Executive
Officer, and Ms. Monique Letourneau, Executive Vice-President, Finance
and Chief Financial Officer.
Interested parties may access the conference call by way of telephone or
webcast. The numbers to access the conference call are 416 644 3417
(international) and 1 800 731 5319 (toll free). The webcast will be
available on the Company's website at www.ambrilia.com, Investors'
section, Conference calls and webcasts, and will be archived for 365 days.
A replay of the call will be available on the Company's website at
www.ambrilia.com, Investors' section, Conference calls and webcasts, from
Monday, August 11, 2008, 11:00 am ET to Monday, August 18, 2008, 11:59 pm
ET, and the numbers to access the replay are 416 640 1917 (international)
and 1 877 289 8525 (toll free) with access code 21278770.
ABOUT AMBRILIA BIOPHARMA
Ambrilia Biopharma Inc. (TSX: AMB) is a biotechnology company focused on
the discovery and development of novel treatments for viral diseases and
cancer. The Company's strategy aims to capitalize on its broad portfolio
and original expertise in virology. Ambrilia's product portfolio is
comprised of oncology and antiviral assets, including two new
formulations of existing peptides for cancer treatment, a therapeutic
peptide for prostate cancer, a targeted delivery technology for cancer,
an HIV protease inhibitor program (exclusive worldwide rights granted to
Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatis
C virus inhibitors and anti-Influenza A compounds. Ambrilia's head
office, research and development and manufacturing facilities are located
in Montreal with a regional office in France.
Contacts:
Ambrilia Biopharma Inc.
Julie M. Thibodeau, B.Sc., MBA
Director, Communications
514-751-2003 ext 235
jthibodeau@ambrilia.com / ir@ambrilia.com
www.ambrilia.com
Copyright 2008, Market Wire, All rights reserved.
-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters